Condition
Upadacitinib
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07472309Completed
Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
NCT07386717Completed
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
NCT06902987Phase 1Recruiting
Efficacy and Safety of Upatinib in the Treatment of Active Anal Fistulas in Crohn's Disease
NCT06573944Unknown
IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study
Showing all 4 trials